Overview

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

Status:
Completed
Trial end date:
2019-05-31
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Curis, Inc.